Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2017; 71(4): 363–364. doi:10.14735/amgh2017363.

Remsima® – the first biosimilar infliximab CT-P13

Milan Lukáš Orcid.org  1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Urbánek K. První biosimilární monoklonální protilátka – infliximab. Klin Farmakol Farm 2014; 28 (1): 19–22.
2. Lukáš M, Kolář M. Biosimilární léčiva u idiopatických střevních zánětů. In: Tesař V (ed.). Biosimilars. Praha: Mladá Fronta 2017. In press.
3. Kolar M, Duricova D, Bortlik M et al. Infliximab bosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis 2017; 35 (1–2):  91–100. doi: 10.1159/000453343.
4. Higgins PD. Comment on article Biosimilar infliximab in anti-TNF naïve IBD patients –  1-year clinical fol­low up. Gastroent Hepatol 2017; 71 (4) : 323–324. doi: 10.14735/amgh2017323. 

Print

Credited self-teaching test

Start test

Most Read (last 6 month)

  1. Colorectal cancer screening in the Czech Republic
  2. Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
  3. Trends in premature mortality from digestive system cancers in Slovakia in the years 2011–2020: 8 diagnoses over 10 years
  4. Results from the evaluation of colorectal cancer screening in the Czech Republic
  5. Mixed adenoneuroendocrine carcinoma of the stomach – a case report
  6. Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
  7. Urolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
  8. Subcutaneous infliximab – treatments and new possibilities after clinical practice